CompletedPhase 2

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

France16 participantsStarted 2009-03

Plain-language summary

The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent * Male or female aged from 18 to 80 years old * Acute adenoviral keratoconjunctivitis Exclusion Criteria: * Active ocular allergy * Ocular herpès disease * History of bacterial conjunctivitis / blepharoconjunctivitis within the last month before the inclusion visit

What they're measuring

efficacy of GV550

Timeframe: D0 to D4

Trial details

NCT IDNCT01156025

SponsorLaboratoires Thea

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-02

View on ClinicalTrials.gov More Acute Adenoviral Keratoconjunctivitis trials